Market Overview

UPDATE: Feltl and Company Raises PT to $121 on DaVita Post Solid Q3

Share:
Related DVA
Earnings Scheduled For May 3, 2018
DaVita Earnings Preview
Orbimed Advisors Llc Buys Bristol-Myers Squibb Company, ARMO BioSciences Inc, Tenet Healthcare ... (GuruFocus)

Feltl and Company reiterated its Buy rating on DaVita (NYSE: DVA) and raised its price target from $111 to $121.

Feltl and Company said, "Solid revenue metrics effectively inline with our expectations: Gross revenue increased 12% over prior year to $2,023 million. Non-acquired revenue increased 4.4%; we believe anything between 4%-5% growth is more than respectable given the mature dynamics of the industry. DVA acquired 10 centers and opened 21 centers in the U.S. and 2 centers outside the U.S. Through three quarters DVA has acquired 71 centers and opened 48 in the U.S. While acquiring facilities can ebb and flow we maintain smaller dialysis operators simply are finding the bundle reimbursement environment more challenging, and we expect continued acquisition activity over the next one to two years."

DaVita closed at $111.02 on Friday.

Latest Ratings for DVA

DateFirmActionFromTo
Jan 2018Bank of AmericaUpgradesNeutralBuy
Dec 2017CitigroupUpgradesNeutralBuy
Dec 2017Raymond JamesUpgradesOutperformStrong Buy

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: Feltl And CompanyAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (DVA)

View Comments and Join the Discussion!